NeuroVive strengthens its organization with the recruitment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 in order to strengthen the company’s communication resources. Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has worked for 15 years, the last eight as Assistant Director Investor Relations & Business Development. She holds a B.Sc in Chemistry and Molecular Biology from Lund University and has completed the Communication Executive Program at the Stockholm School of Economics. “One of my priorities as NeuroVive’s new CEO is to strengthen our communication team. Cecilia’s communications expertise combined with her experience of the biotech industry will make a valuable contribution,” commented NeuroVive’s CEO Erik Kinnman. Apart from IR and Communication, Cecilia Hofvander’s broad experience includes business development, financial transactions and international clinical trials with drug candidates. “NeuroVive has a very promising project portfolio and is in an exciting phase with the results of clinical trials due to be presented over the coming year. I look forward to contributing to the company’s development by communicating NeuroVive’s and its partners’ activities and drug development progress. In my communication work, my priorities are openness and clarity as a means to building long-term relationships with the company’s stakeholders,” commented Cecilia Hofvander. Christine Tadgell from InVentive Health will coordinate NeuroVive’s external communication in the period until Cecilia Hofvander takes up her position with NeuroVive. The company’s collaboration with IR firm Laika Consulting will also continue. About NeuroVive NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden. For investor relations and media questions, please contact: Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com, www.neurovive.com NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 08.30 CET on 11 April 2016. NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/NE V PF/quot)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 108

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 50

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 59

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading

Top 5 Most Recently Viewed Articles

Kraft Heinz Faces Major Challenges Amid Declining Sales

Updated Category News Views 277

Kraft Heinz Faces Significant Challenges in the Market In the vast landscape of the food industry, Kraft Heinz is confronting a myriad of challenges that could jeopardize its long-term viability. As I analyzed the company's latest financial results and corporate strategy, it became evident that Kraft Heinz is facing serious structural issues. Despite the allure of its...

Continue Reading
Exploring the Future of the Software Defined Vehicle Market

Updated Category News Views 261

Understanding the Software Defined Vehicle Market The software defined vehicle market has become a focal point in the automotive industry due to the rapid advancements in technology. A key driver of this trend is the growing demand for advanced driver assistance systems (ADAS) and the increasing interest in autonomous and connected vehicles. Market Dynamics Fueling Growth...

Continue Reading
Open Lending Corporation Under Scrutiny: A Legal Recourse Awaits Investors

Updated Category News Views 169

Introduction to Open Lending Corporation Open Lending Corporation is a significant player in the auto finance sector, focusing on risk-based pricing solutions. They provide platforms that facilitate lenders' access to a broader market in the automotive financing ecosystem. However, the company faces serious allegations from investors claiming violations of securities...

Continue Reading
Cognex Corporation's Financial Performance: Q3 Insights

Updated Category News Views 303

Cognex Corporation Financial Results Overview Cognex Corporation (NASDAQ: CGNX) recently shared its financial outcomes for the third quarter of 2025, showcasing remarkable growth and strategic advancements within its operations. As a global leader in industrial machine vision, Cognex reported strong revenue growth largely driven by demand in automation technologies across...

Continue Reading
IBA and Jabil Enhance Sterilization Technology Through Partnership

Updated Category News Views 496

IBA and Jabil Collaborate on Innovative Sterilization Solutions In an exciting development, IBA (Ion Beam Applications S.A.), renowned for its leadership in particle accelerator technology, has joined forces with Jabil Inc., a global leader in manufacturing and supply chain solutions. This collaboration marks a significant step forward in sterilization technology,...

Continue Reading